Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.68 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.68 |
| ▸ | DRD3 | P35462 | 2/20 | 0.68 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.68 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.66 |
| ▸ | LMNA | P02545 | 3/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.64 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.64 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.64 |
| ▸ | MC4R | P32245 | 1/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lanperisone SCHEMBL570832 | 1.00 | CHRM2 (0.68) | CHRM2ADRA2BDRD3SIGMAR1HRH3 | |
| Lanperisone SCHEMBL1987393 | 0.99 | ALDH1A1 (0.68) | CHRM2ADRA2BDRD3SIGMAR1HRH3 | |
| Lanperisone SCHEMBL5819985 | 0.99 | ALDH1A1 (0.68) | CHRM2ADRA2BDRD3SIGMAR1HRH3 | |
| SCHEMBL9720545 | 0.99 | CHRM2 (0.70) | CHRM2ADRA2BDRD3SIGMAR1HRH3 | |
| SCHEMBL13058950 | 0.88 | ALDH1A1 (0.67) | CHRM2ADRA2BDRD3SIGMAR1HRH3 | |
| SCHEMBL9168033 | 0.87 | CHRM2 (0.69) | CHRM2ADRA2BDRD3SIGMAR1HRH3 | |
| SCHEMBL10851001 | 0.86 | SIGMAR1 (0.72) | CHRM2ADRA2BDRD3SIGMAR1HRH3 | |
| SCHEMBL17832656 | 0.83 | CHRM2 (0.46) | CHRM2ADRA2BDRD3SIGMAR1HRH3 | |
| Lanperisone SCHEMBL9820433 | 0.83 | CHRM2 (0.60) | CHRM2ADRA2BDRD3SIGMAR1HRH3 | |
| SCHEMBL12123621 | 0.82 | CHRM2 (0.76) | CHRM2ADRA2BDRD3SIGMAR1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0200942-B1 | NEW DERIVATIVES OF AN AMINOKETONE | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1993-08-25 | — | — | EP | claimed |
| US-5103022-A | Reacting dl-2-methyl-1-(4-trifluoromethylphenyl)-3-pyrrolidino -1-propanone with l-acetylphenylglycine to form corresponding diastereomeric salt, deposition, isolation of l-2-methyl-1-(4-trifluoromethylphenyl)-3-pyrrolidino-1-propanone | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1992-04-07 | — | — | US | claimed |
| US-5057535-A | Muscle relaxants | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1991-10-15 | — | — | US | claimed |
| EP-0266577-B1 | AN OPTICALLY ACTIVE PROPANONE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME AND USE THEREOF | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1991-09-25 | — | — | EP | claimed |
| EP-0266577-A1 | An optically active propanone derivative and process for producing the same and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1988-05-11 | — | — | EP | claimed |
| EP-0200942-A2 | New derivatives of an aminoketone | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1986-11-12 | — | — | EP | claimed |
| JP-63225367-A | — | — | None | — | — | JP | disclosed |
| JP-1131171-A | — | — | None | — | — | JP | disclosed |
| JP-63310878-A | — | — | None | — | — | JP | disclosed |
| JP-7179446-A | — | — | None | — | — | JP | disclosed |
| US-20100298329-A1 | TOLPERISONE AND TOLPERISONE-LIKE DRUGS FOR THE TREATMENT OF K-RAS ASSOCIATED CANCERS | MASSACHUSETTE INSTITUTE OF TECHNOLOGY (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298329-A1 | TOLPERISONE AND TOLPERISONE-LIKE DRUGS FOR THE TREATMENT OF K-RAS ASSOCIATED CANCERS | MASSACHUSETTE INSTITUTE OF TECHNOLOGY (US) | 2010-11-25 | — | — | US | disclosed |
| WO-2009038771-A2 | TOLPERISONE AND TOLPERISONE-LIKE DRUGS FOR THE TREATMENT OF K-RAS ASSOCIATED CANCERS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2009-03-26 | — | — | WO | disclosed |
| CN-1013441-B | Process for preparing optically active acetone derivatives | NIPPON KAYAKN K K (JP) | 1991-08-07 | — | — | CN | disclosed |
| JP-H01131171-A | OPTICALLY ACTIVE PROPANONE DERIVATIVE AND PRODUCTION THEREOF | NIPPON KAYAKU CO LTD | 1989-05-24 | — | — | JP | disclosed |
| JP-S63310878-A | RECOVERY OF PROPANONE DERIVATIVE | NIPPON KAYAKU CO LTD | 1988-12-19 | — | — | JP | disclosed |
| JP-S63225367-A | OPTICALLY ACTIVE PROPANONE DERIVATIVE AND PRODUCTION THEREOF | NIPPON KAYAKU CO LTD | 1988-09-20 | — | — | JP | disclosed |
| EP-0266577-A1 | An optically active propanone derivative and process for producing the same and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1988-05-11 | — | — | EP | disclosed |
| EP-0266577-A1 | An optically active propanone derivative and process for producing the same and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1988-05-11 | — | — | EP | disclosed |
| EP-0200942-A2 | New derivatives of an aminoketone | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1986-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298329-A1 | TOLPERISONE AND TOLPERISONE-LIKE DRUGS FOR THE TREATMENT OF K-RAS ASSOCIATED CANCERS | NRAS, KRAS, RASGRP1 | CHRM2 4614/4885ADRA2B 2168/4885DRD3 3346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.